Breast Milk Antibodies Could Become a New Flu Defense

Breast Milk Antibodies recovered from donated breast milk shielded lab-grown cells and animals from respiratory syncytial virus, adenovirus and influenza — including the H5N1 bird flu strain — in a new study that hints at a future where the defenses mothers pass to babies could protect far more people. The work, published in the journal Science Advances in mid-October, found that delivering the antibodies through the nose gave test animals complete protection, even animals with weakened immune systems, according to a report from the Canadian university behind the research.

The idea builds on passive immunization, a strategy that hands the body ready-made antibodies instead of waiting for it to manufacture its own after a shot or an infection. "Passive immunization allows people to immediately benefit from antibodies produced in the lab or collected from other people, instead of relying on their own immune systems to produce them in response to infection or vaccination," said Matthew Miller, a biochemistry professor at McMaster University and the study's principal investigator. Miller told the university's news team the approach is particularly useful for people with immune deficiencies and could become a rapid-response measure during outbreaks and pandemics. That framing matters because current antibody therapies are often infused directly into the bloodstream, a slower and more clinical route than a nasal dose.

From donated milk to a virus-fighting cocktail

The Breast Milk Antibodies used in the experiments were not drawn from a single source, because no two donors carry the same immune history. The team collected milk samples from 120 donors through milk banks in Indianapolis and Pittsburgh, purified a class of antibodies known as immunoglobulin A, and pooled the samples so the final mixture reflected many different infection and vaccination histories. "The antibodies that are found in breast milk are essentially a record of what a mother has encountered, either through vaccination or through infection," said Sam Afkhami, operations manager at the university's NexusHealth unit and a co-corresponding author on the paper. Breastfeeding lets mothers hand those antibodies to babies as stopgap protection until infant immunizations kick in, Afkhami explained — and the study's logic is that the same handoff could work for other people too.

Pooling was the key move. One person's milk might carry defenses against a virus their neighbor never met, so combining donations produced a broader shield than any single sample could offer. The researchers, working with the US biotechnology company Lactiga, then tested the pooled mixture against three respiratory viruses in lab-grown cells: RSV, adenovirus and influenza A. In each case the mixture neutralized the virus, showing antiviral activity across a wide spectrum rather than against one narrow target.

Why the nose beat the needle

The team went further than cell cultures. They also tested the milk-derived antibodies in animal models of infection, comparing mucosal delivery — a dose through the nose — against the bloodstream infusions typical of existing antibody treatments. The nasal route provided complete protection, including in animals whose immune systems were compromised. "It's a viable strategy," said Yona Tugg, a PhD candidate in Miller's lab and the paper's first author. "There's still so much to learn about mucosal immunity, but between this study and McMaster's inhaled vaccine work, it's clear that people can generate important, protective responses across their mucosal sites. There should be greater focus on enhancing this type of protection going forward."

The contrast with how antibody drugs are usually given is the point. An infusion reaches the blood; a nasal dose meets respiratory viruses at the door. For people whose immune systems cannot mount a strong response to vaccines — transplant recipients, some cancer patients, people with primary immune disorders — a ready-made nasal shield could fill a gap that shots leave open. That is also why the researchers see outbreak potential: during a fast-moving pandemic, a passive treatment that works immediately could buy time while vaccines are developed and distributed.

What this could mean beyond babies

Turning Breast Milk Antibodies into a real treatment would take years, and the researchers are not pretending otherwise. No human trials have started, and scaling up would require a far larger donor network than the milk banks that supplied this study. There are also open questions about dosing, shelf life and how regulators would classify a pooled human-milk product. Still, the team describes breast milk as a scalable and sustainable source of diverse antibodies, which is a notable claim: most antibody drugs are manufactured cell by cell in expensive bioreactors, while donor milk is a renewable resource that already flows through established milk banks.

For readers, the honest takeaway is narrower than the headline promise but still meaningful. This is early-stage science, not a product — nobody should expect a milk-antibody nasal spray at the pharmacy this flu season. But the study reframes something many people take for granted. Breast milk has long been understood as nutrition plus a little immune help for infants; this work treats it as a library of human immune memory that science has barely started to read. Early medical findings deserve the same careful reading we give other first-wave results, like the observational study linking antidepressants to cancer immunotherapy outcomes, where correlation and causation are easy to confuse. And it is a reminder of how fast lab science now travels into everyday conversation — the same week, group chats were busy dissecting the viral "boy kibble" protein bowl trend, proof that what we eat, and what our bodies make from it, is never far from the discourse. If follow-up studies confirm these results in people, the humble milk bank could one day sit beside the vaccine clinic as a pillar of outbreak defense.